You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

How Does Weight in Childhood Affect Menstruation as an Adult?

  • Authors: News Author: Jake Remaly; CME Author: Laurie Barclay, MD
  • CME / ABIM MOC / CE Released: 4/15/2022
  • THIS ACTIVITY HAS EXPIRED FOR CREDIT
  • Valid for credit through: 4/15/2023
Start Activity


Target Audience and Goal Statement

This activity is intended for obstetricians/gynecologists/women's health clinicians, pediatricians, diabetologists/endocrinologists, family medicine/primary care practitioners, internal medicine clinicians, nurses, physician assistants, and other members of the health care team who treat and manage overweight girls who may be at risk for menstrual problems in adulthood.

The goal of this activity is that learners will be better able to describe the association between childhood and adolescent body mass index and risk for premenstrual disorders in young adulthood, based on a prospective cohort study of US female participants in the Growing Up Today Study (GUTS: 1996-2013).

Upon completion of this activity, participants will:

  • Assess the association between childhood and adolescent body mass index and risk for premenstrual disorders in young adulthood, based on a prospective cohort study of US female participants in the Growing Up Today Study
  • Evaluate the clinical implications of the association between childhood and adolescent body mass index and risk for premenstrual disorders in young adulthood, based on a prospective cohort study of US female participants in the Growing Up Today Study
  • Outline implications for the healthcare team


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


News Author

  • Jake Remaly

    Freelance writer, Medscape

    Disclosures

    Disclosure: Jake Remaly has disclosed no relevant financial relationships.

CME Author

  • Laurie Barclay, MD

    Freelance writer and reviewer
    Medscape, LLC

    Disclosures

    Disclosure: Laurie Barclay, MD, has disclosed the following relevant financial relationships:
    Stocks, stock options, or bonds: AbbVie (former)

Editor/Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Disclosure: Yaisanet Oyola, MD, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance
    Medscape, LLC

    Disclosures

    Disclosure: Amanda Jett, PharmD, BCACP, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 

This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0 contact hours are in the area of pharmacology.

    Contact This Provider

  • For Physician Assistants

    Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 4/15/2023. PAs should only claim credit commensurate with the extent of their participation.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

How Does Weight in Childhood Affect Menstruation as an Adult?

Authors: News Author: Jake Remaly; CME Author: Laurie Barclay, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 4/15/2022

Valid for credit through: 4/15/2023

processing....

Clinical Context

Data suggests that more than two-thirds of premenstrual disorders (PMDs) have symptom onset during the teen years. Premenstrual disorders can include premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). PMDD is more disabling due to the predominant psychological symptoms and social functioning problems. Few risk factors in early life have been identified for PMD development.

Higher body mass index (BMI) may be a consequence of premenstrual symptoms rather than a contributor. Prospective data are needed to clarify a potential causal relationship between childhood BMI and subsequent risk for PMDs.

Study Synopsis and Perspective

Above-normal body mass in childhood is a risk factor for premenstrual disorders in adulthood, a new study has found.

The results suggest that maintaining a normal weight as a preadolescent may lower the burden of premenstrual disorders later on, according to the researchers, whose study was published online March 8 in JAMA Network Open.[1]

"Healthcare providers should be aware of the risk of premenstrual disorders among children with bigger body mass and educate the girls and their parents about the premenstrual symptoms," such as mood swings, hypersensitivity, insomnia, fatigue, and food cravings, said Donghao Lu, MD, PhD, from the Karolinska Institute in Stockholm, Sweden, who led the study.

Although prior cross-sectional studies have shown correlations between BMI and premenstrual disorders, whether one condition leads to the other has been unclear.

"The thinking was that premenstrual disorders might contribute to weight gain because premenstrual syndrome usually includes cravings and mood changes," Chighaf Bakour, MD, PhD, University of South Florida, Tampa, who authored an accompanying editorial, told Medscape Medical News.[2]

Identifying PMS and PMDD

To examine the association between childhood body size and the risk for premenstrual disorders in young adulthood, Dr Lu and colleagues analyzed data from 6,524 US women participating in the Growing Up Today Study (GUTS), which includes children of participants in the Nurses' Health Study II.

The investigators enrolled more than 16,800 children aged 9 to 14 years in the first phase of GUTS in 1996. In a second phase in 2004, researchers recruited nearly 11,000 other children aged 9 to 16 years. Participants reported their height and weight on questionnaires. In 2013 they completed a questionnaire about premenstrual symptoms.

About 15% met criteria for premenstrual disorders, including premenstrual syndrome and premenstrual dysphoric disorder, a more disabling form in which psychologic symptoms predominate and impair social functioning.

Baseline BMI, at an average age of 12.7 years, was positively associated with the risk for premenstrual disorders at a mean age of 26 years, with a risk ratio of 1.09 per unit of BMI z score (95% confidence interval [CI], 1.03-1.15).

The researchers also found a trend of increasing premenstrual symptom severity across BMI categories.

"Obesity was associated with a higher burden of premenstrual symptoms (β = 0.27; 95% CI, 0.09-0.44) compared with normal BMI for age," they write. After adjusting for potential mediators like age at menarche, obesity's association with symptoms remained significant but "slightly attenuated," they say.

Women with premenstrual disorders experienced menarche slightly earlier, on average, than women without the conditions (12.7 vs 12.8 years). They also were more likely to report experiences of childhood abuse (27.8% vs 21.3%), to smoke, and to have anxiety, depression, and disordered eating based on self-reported diagnoses, medication use, or reported symptoms.

Prior studies have shown that early menarche and adverse childhood experiences also are associated with increased risk for premenstrual disorders, Dr Lu noted.[3,4]

Opportunity for Intervention?

The researchers speculated that the interplay between fat and sex hormones could contribute to the increased risk. Another possibility, they added, is that an inflammatory response to obesity somehow triggers the development of premenstrual disorders.

But many women with PMDs may have had normal body mass as children. "Of course, we don't believe larger body size is the only player here," Dr Lu told Medscape Medical News.

The study does not establish that overweight or obesity causes premenstrual disorders, Dr Bakour writes in her commentary to the study. Other, unmeasured variables related to adverse childhood environments or diet, for example, might contribute to the development of both weight gain and premenstrual syndrome.

The next step, she said, would be to look at what might contribute to both disorders: "Something like depression, mental illness, or toxic stress would contribute to overweight and also increase premenstrual disorders," she told Medscape Medical News. The study also paves the way for interventional studies to test whether weight management can reduce the incidence or burden of premenstrual disorders.

The study was supported by Swedish Research Council grants. The Growing Up Today Study was supported by the National Institutes of Health. Study coauthors disclosed grants from the National Institutes of Health and work on a study for the Swedish Inflammatory Bowel Disease Register, which receives funding from Janssen. Dr Bakour has disclosed no relevant financial relationships.

JAMA Netw Open. Published online March 8, 2022.

Study Highlights

  • The prospective cohort for this study included 6524 US female participants in GUTS (1996-2013).
  • Mean age was 26±3.5 years, 93.6% were White, and 15.4% met criteria for PMD.
  • BMI was estimated from self-reported height and weight through adolescence and converted to BMI for age (z score).
  • Premenstrual symptoms and PMDs were evaluated in 2013, using a validated scale based on the Calendar of Premenstrual Experiences.
  • Log-binomial and linear regressions examined associations of BMI for age with PMDs and premenstrual symptoms.
  • Baseline BMI for age reported at mean age 12.7 was associated with increased risk for PMDs (confounding-adjusted relative risk, 1.09 per unit of z score; 95% CI, 1.03-1.15) and higher burden of premenstrual symptoms (β=0.06; 95% CI, 0.04-0.08).
  • Associations were stronger for PMDD and for PMDs with symptom onset before age 20 years and remained in the absence of psychiatric comorbidities, including depression, anxiety, and disordered eating behavior.
  • Timing of menarche moderately mediated the association of premenarchal BMI on PMDs, but higher risk remained after adjusting for other potential mediators, including smoking and oral contraceptive use.
  • Analysis of BMI change over time showed that individuals with high vs normal BMI throughout adolescence had a higher burden of premenstrual symptoms (β=0.17; 95% CI, 0.08-0.27).
  • Individuals with high BMI early followed by a mild decrease later did not report higher premenstrual symptoms (β=0.06; 95% CI, 0.00-0.12).
  • Adjustment for potential confounders including age at menarche slightly attenuated the association of obesity with premenstrual symptoms.
  • Women with vs without PMDs underwent menarche slightly earlier (average, 12.7 vs. 12.8 years) and had more reports of childhood abuse (27.8% vs 21.3%), smoking, and anxiety, depression, and disordered eating, based on self-reported diagnoses, medication use, or reported symptoms.
  • BMI across ages 11 to 18, but not earlier ages, was positively associated with premenstrual symptom severity.
  • The investigators concluded that childhood body size was associated with PMD risk and premenstrual symptoms in young adulthood, particularly for probable PMDD and early-onset PMDs (onset <20 years), and appeared to be independent of psychiatric comorbidities.
  • If the findings are confirmed in independent populations, maintaining normal BMI in childhood may be considered to prevent development of PMDs, as well as of other health conditions, in adulthood.
  • Future research is needed to clarify further how specific ages at exposure to adiposity relate to PMD risk.
  • Nonincreased risk among individuals with larger BMI in early adolescence but leaner body mass later may inform development of PMD prevention strategies.
  • The association of childhood adiposity with depression, anxiety, and eating disorder later in life may partly explain the association between childhood BMI and PMDs, but the latter associations occurred even in the absence of common psychiatric comorbidities.
  • Childhood obesity may also result in early menarche, which is associated with increased risk for PMDs.
  • Overall pubertal timing could mediate the association between childhood BMI and PMDs, but associations with BMI mostly remained significant even after accounting for age at menarche.
  • The interplay between adiposity and sex hormones could also contribute to increased risk for PMDs, as could the chronic inflammatory response to obesity.
  • Study limitations include potential misclassification of body shape and PMDs; inability of BMI to directly assess body fat distribution; and possible residual confounding.
  • An invited commentary noted that the findings support the hypothesis that childhood and adolescent BMI is a risk factor for PMS symptoms and possibly the occurrence of PMDs by young adulthood, but the level of evidence was insufficient to infer causality.
  • Prospective studies starting in early childhood with follow-up through young adulthood and interventional studies examining the association of sustained weight loss in childhood and adolescence with PMD incidence and burden are still needed.

Clinical Implications

  • Childhood BMI was associated with PMD risk and premenstrual symptoms in young adulthood, particularly for probable PMDD and early-onset PMDs.
  • As the study could not prove causality, prospective studies starting in early childhood with follow-up through young adulthood and interventional studies examining the association of sustained weight loss in childhood and adolescence with PMD incidence and burden are still needed.
  • Implications for the Health Care Team: Childhood obesity may also result in early menarche, which is associated with increased risk for PMDs. The overall pubertal timing could mediate the association between childhood BMI and PMDs, but associations with BMI mostly remained significant even after accounting for age at menarche. It was found that maintaining normal BMI in childhood may be considered a measure to prevent development of PMDs and other health conditions in adulthood, clinician’s and members of the health care team must share this information with their patients and care holders.

 

Earn Credit

  • Print